Authorization

Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer's Disease

-- Oligomannate , A New Oral Treatment For Mild To Moderate Alzheimer's Disease -- The Only Approved Novel AD Treatment Globally Since 2003SHANGHAI, Nov. 2, 2019 /PRNewswire/ --A Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China'sA National Medical Products AdministrationA (NMPA)A has approved Oligomannate (GV-971) asA new drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function." NMPA granted Oligomannate for fast-track review in November 2018. A It is the first novel drug approved for Alzheimer's disease globally since 2003. A Oligomannate will provide a new treatment option to fight Alzheimer's diseaseA for patients and is expected to be available in China by the end of 2019.Study Results
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2020    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031